SAREPTA THERAPEUTICS
Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare diseases. It specializes in gene therapy, RNA-targeted exon skipping, and gene editing. It was founded in 1980 and headquartered in Cambridge, Massachusetts.
SAREPTA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
1980-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.sarepta.com
Total Employee:
501+
Status:
Active
Contact:
5417543545
Email Addresses:
[email protected]
Total Funding:
1.38 B USD
Technology used in webpage:
SPF Domain Not Resolving Amazon Microsoft Azure DNS Amazon Virginia Region DMARC Mimecast ASP.NET 2.0 Symantec.cloud EasyDNS
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Corvidia
Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Horizon Pharma
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-02-27 | Myonexus Therapeutics | Myonexus Therapeutics acquired by Sarepta Therapeutics | 165 M USD |
| 2014-07-07 | Eisai | Eisai acquired by Sarepta Therapeutics | 25 M USD |
| 2008-03-12 | Ercole Biotech | Ercole Biotech acquired by Sarepta Therapeutics | N/A |
Investors List
Roche Financial
Roche Financial investment in Post-IPO Equity - Sarepta Therapeutics
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - Sarepta Therapeutics
MidCap Financial
MidCap Financial investment in Post-IPO Debt - Sarepta Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-16 | StrideBio | Sarepta Therapeutics investment in Series B - StrideBio | 81.5 M USD |
| 2020-10-22 | AavantiBio | Sarepta Therapeutics investment in Series A - AavantiBio | 107 M USD |
| 2018-08-09 | Lacerta Therapeutics | Sarepta Therapeutics investment in Venture Round - Lacerta Therapeutics | 30 M USD |
| 2018-05-08 | Myonexus Therapeutics | Sarepta Therapeutics investment in Corporate Round - Myonexus Therapeutics | 60 M USD |
Official Site Inspections
http://www.sarepta.com Semrush global rank: 1.15 M Semrush visits lastest month: 27.55 K
- Host name: ec2-54-204-43-126.compute-1.amazonaws.com
- IP address: 54.204.43.126
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Sarepta Therapeutics"
Investor Relations | Sarepta Therapeutics, Inc.
The Investor Relations website contains information about Sarepta Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Sarepta Therapeutics - Wikipedia
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.See details»
Sarepta Therapeutics - Crunchbase Company Profile
Sarepta Therapeutics is a biopharmaceutical company that focuses on the discovery and development of precision genetic medicine to treat rare …See details»
Sarepta overhaul includes 500 layoffs, gene therapy program cuts
Jul 16, 2025 Sarepta has also announced an FDA-requested black box warning be included on Elevidys’ label for acute liver injury and failure.See details»
Sarepta to lay off about 500 employees after Duchenne …
Jul 16, 2025 Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks On a conference call, CEO Doug Ingram said the decision to cut 36% of the company’s staff and halt several drug programs was essential to …See details»
Meet Our Leadership | Sarepta Therapeutics
Learn about Sarepta's leadership and their goal to forever change the course of genetic disease.See details»
Sarepta Therapeutics | Biopharmaceutical Company for …
Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.See details»
Sarepta Therapeutics: What's Happening With SRPT Stock? - Forbes
Jul 17, 2025 The restructuring presents an exciting turnaround narrative — reorienting Sarepta from a high-spending, pipeline-heavy biotech into a streamlined organization focused on its …See details»
Sarepta Therapeutics Announces Strategic Restructuring and …
Jul 16, 2025 “Faced with environmental changes, we have decided to act decisively, implementing a focused strategy to ensure Sarepta remains a vibrant, financially enduring, …See details»
Welcome to SareptAcademy | Sareptacademy
Welcome to SareptAcademy A COMMUNITY RESOURCE CENTER At Sarepta, we are committed to a patients-come-first approach. We are working directly with people living with …See details»
Recapping the Sarepta Saga—And Implications for Industry
2 days ago A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential future impacts for gene therapy regulation …See details»
Sarepta shakes up C-suite amid org overhaul—Chutes & Ladders
Jul 18, 2025 Sarepta shakes up C-suite amid organization overhaul. BioNTech strategy chief seeks new adventure. Prime’s CSO hits the exit.See details»
About Our Company | Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new …See details»
Sarepta Warnings Came Long Before Its Standoff With US Regulators
3 days ago Source: Sarepta Therapeutics Inc. FDA leaders met with Sarepta, the agency said in a statement Friday, and requested it voluntarily stop all shipments of the drug, which is its …See details»
Sarepta: Safety And Efficacy Flaws Undermine Gains On …
Jul 17, 2025 Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.See details»
Sarepta to cut 500 jobs after gene therapy setback - Reuters
Jul 16, 2025 Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the …See details»
Sarepta Therapeutics Announces Strategic Restructuring and …
Jul 16, 2025 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan designed...See details»
Our Pipeline | Sarepta Therapeutics
Apr 8, 2025 Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and …See details»
Sarepta Therapeutics Announces Strategic Restructuring and …
Jul 16, 2025 – After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets – Strategic restructuring includes …See details»
Sarepta Cuts 500 Jobs, Refocuses Pipeline on siRNAs in …
Jul 17, 2025 NEW YORK – Sarepta Therapeutics on Wednesday said it would pivot to focus its rare genetic disease pipeline on siRNA drugs as part of a strategic restructuring plan to …See details»